Literature DB >> 6612639

Effect of the antitussive glaucine on bronchomotor tone in man.

O Constant, B Slavin, J R Lehane, C Jordan, J G Jones.   

Abstract

In view of the observation that the antitussive agent glaucine prevents histamine-induced bronchoconstriction in guinea pigs we investigated this agent for a possible peripheral action in man, using a new method for measuring changes in bronchomotor tone. The forced airflow oscillation method was used to determine respiratory resistance (Rrs) over a range of lung volumes (VL) in seven healthy supine subjects. Computer analysis of the hyperbolic relationship between Rrs and VL was used to determine the asymptotic resistance and yield estimates of lower airways conductance (Glaw). Specific lower airways conductance (sGlaw) was expressed as the slope of the linear plot of Glaw against VL and is a sensitive index of bronchomotor tone. After baseline measurements of sGlaw subjects received placebo or 60 mg glaucine orally according to a double-blind crossover protocol. Histamine, 500 micrograms, was inhaled 45 minutes later. Measurements of sGlaw were repeated every 10 minutes for two hours. Although there was a trend towards bronchodilatation after glaucine administration (sGlaw = 130% of baseline) there was no significant difference from the effect of placebo (sGlaw = 89% of baseline). After inhalation of histamine sGlaw fell to 26% of baseline after both glaucine and placebo (p less than 0.01). In a further study three subjects received glaucine and placebo according to an identical protocol except that the histamine was omitted. Again the increase in sGlaw failed to achieve significance. Glaucine does not affect the bronchoconstrictor response to histamine in man and there is no convincing evidence of an effect on resting bronchomotor tone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6612639      PMCID: PMC459602          DOI: 10.1136/thx.38.7.537

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  MEASUREMENT OF UPPER AND LOWER AIRWAY RESISTANCE AND CONDUCTANCE IN MAN.

Authors:  R W BLIDE; H D KERR; W S SPICER
Journal:  J Appl Physiol       Date:  1964-11       Impact factor: 3.531

2.  Direct writeout of total respiratory resistance.

Authors:  R E Hyatt; I R Zimmerman; G M Peters; W J Sullivan
Journal:  J Appl Physiol       Date:  1970-05       Impact factor: 3.531

3.  A simplified measurement of respiratory resistance by forced oscillation.

Authors:  M Goldman; R J Knudson; J Mead; N Peterson; J R Schwaber; M E Wohl
Journal:  J Appl Physiol       Date:  1970-01       Impact factor: 3.531

4.  Influence of halothane and enflurane on respiratory airflow resistance and specific conductance in anaesthetized man.

Authors:  J R Lehane; C Jordan; J G Jones
Journal:  Br J Anaesth       Date:  1980-08       Impact factor: 9.166

5.  Chronic cough as the sole presenting manifestation of bronchial asthma.

Authors:  W M Corrao; S S Braman; R S Irwin
Journal:  N Engl J Med       Date:  1979-03-22       Impact factor: 91.245

6.  Specific conductance using forced airflow oscillation in mechanically ventilated human subjects.

Authors:  C Jordan; J R Lehane; J G Jones; D G Altman; J P Royston
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1981-09

7.  Experimental studies of the abuse potential of d, l-glaucine. 1.5-phosphate in rhesus monkeys.

Authors:  C R Schuster; T Aigner; C E Johanson; T H Gieske
Journal:  Pharmacol Biochem Behav       Date:  1982-05       Impact factor: 3.533

8.  Double-blind study of glaucine in chronic cough.

Authors:  P Dierckx; G Leblanc; A Decoster; D Criscuolo
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-09
  8 in total
  1 in total

1.  Bronchodilator and anti-inflammatory activities of glaucine: In vitro studies in human airway smooth muscle and polymorphonuclear leukocytes.

Authors:  J Cortijo; V Villagrasa; R Pons; L Berto; M Martí-Cabrera; M Martinez-Losa; T Domenech; J Beleta; E J Morcillo
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.